Objective: To explore the effect of GLP-1 receptor agonist combined with metformin tablets on liver fibrosis, PTX3 and TXNIP in patients with NAFLD. Methods: 308 non-alcoholic fatty liver disease (NAFLD) patients admitted to our hospital from May 2016 to June 2019 were selected and randomly divided into the observation group and control group, with 154 cases in each group. Patients in the control group were treated with metformin tablets, and patients in the observation group were treated with the GLP-1 receptor agonist liraglutide combining with metformin tablets. The total cholesterol (TC) and triacylglycerol (TG) , low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting plasma glucose (FPG), postprandial 2 h blood glucose (2 h PG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), insulin resistance index (HOMA-IR), serum hyaluronic acid (HA), laminin (LN), type IV collagen (IV-C), Ⅲ Type procollagen (PCⅢ), aspartate aminotransferase (AST), alanine aminotransferase (ALT), liver fibrosis score (NAFLDFS), serum pentameric protein-3 (PTX3) and serum thioredoxin, and the expression level of protein interaction protein (TXNIP) of the two groups were compared before and after treatment. Results: After treatment, the levels of TC, TG, LDL-C, FPG, 2hPG, HbA1c in the two groups were lower than those before treatment, and the levels of above indicators in the observation group was lower than those in the control group (P＜0.05), while the HDL-C levels in the two groups were higher than those before treatment, and the HDL-C level of the observation group was higher than that of the control group (P＜0.05). After treatment, the levels of FPG, FINS and HOMA-IR in the observation group were lower than those before treatment, and were significantly lower than those in the control group (P＜0.05). The FPG level in the control group was higher than that before treatment, while FINS and HOMA-IR were higher after treatment (P＜0.05). After treatment, the levels of liver fibrosis indexes such as LN, IV-C, PCⅢ, HA, AST, ALT and NAFLDFS score of the two groups were significantly lower than those before treatment, and the levels of above indicators of observation group was lower than those in the control group (P＜0.05). The serum TXNIP and PTX3 levels of patients in the two groups were significantly lower than those before treatment, and they were lower in the observation group than those in the control group, and the differences were statistically significant (P＜0.05). Conclusion: GLP-1 receptor agonists combined with metformin tablets could effectively alleviate liver fibrosis in patients with NAFLD, improve insulin resistance, reduce the expression of serum PTX3 and TXNIP levels, and improve patients’ liver function.
[1] 邓丽红, 刘添皇, 何宗运, 等. 二甲双胍辅助治疗对NAFLD患者肝纤维化和胰岛素抵抗的影响[J]. 中国医药科学, 2018, 8(19): 92-94.
[2] Daneshi-Maskooni M, Keshavarz SA, Qorbani M, et al. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial[J]. BMC Complement Altern Med, 2019, 19(1): 59.
[3] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156(6): 1717-1730.
[4] 易默, 周健, 史丽萍, 等. 多烯磷脂酰胆碱联合二甲双胍治疗对非酒精性脂肪性肝病患者肝纤维化、血浆抵抗素与胰岛素抵抗的影响[J]. 中国中西医结合消化杂志, 2017, 25(9): 641-645.
[5] Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Gastroenterology, 2020, 158(6): 1611-1625. e12.
[6] Gao F, Huang JF, Zheng KI, et al. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2020, 35(10): 1804-1812.
[7] Yeh WJ, Ko J, Huang WC, et al. Crude extract of Camellia oleifera pomace ameliorates the progression of non-alcoholic fatty liver disease via decreasing fat accumulation, insulin resistance and inflammation[J]. Br J Nutr, 2020, 123(5): 508-515.
[8] 严妍, 吴新华, 黄玉杰, 等. 利拉鲁肽对2型糖尿病合并NAFLD患者肝功能,脂代谢及微炎性反应的影响[J]. 疑难病杂志, 2019, 18(10): 1009-1012.
[9] Furlan A, Tublin ME, Yu L, et al. Comparison of 2d shear wave elastography, transient elastography, and mr elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease[J]. AJR Am J Roentgenol, 2020, 214(1): W20-W26.
[10] Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Diabetes Obes Metab, 2019, 21(2): 285-292.
[11] 林琴, 符鸿俊, 杨远行, 等. 利拉鲁肽治疗2型糖尿病合并非酒精性脂肪肝的疗效评价[J]. 中国卫生检验杂志, 2018, 28(21): 2626-2628, 2631.
[12] Jiang WX, Huang SR, Teng H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis[J]. BMJ Open, 2018, 8(8): e021787.
[13] Darweesh SK, AbdElAziz RA, Abd-ElFatah DS, et al. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients[J]. Eur J Gastroenterol Hepatol, 2019, 31(5): 633-641.
[14] 贾晨, 张涛, 王浩, 等. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂,血管内皮功能和肝纤维化指标的变化[J]. 实用肝脏病杂志, 2020, 23(2): 57-60.
[15] Lemoine M, Assoumou L, de Wit S, et al. Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease(NAFLD): results from the ECHAM study[J].J Acquir Immune Defic Syndr, 2019, 80(4): e86-e94.
[16] 韩淑琴, 刘润, 刘俊霞, 等. 二甲双胍对2型糖尿病合并非酒精性脂肪性肝病患者肝脏炎症、肝纤维化和胰岛素抵抗的影响[J]. 河北医药, 2018, 40(12): 1769-1773.
[17] Aso Y, Kato K, Sakurai S, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease[J].Int J Clin Pract, 2019, 73(5): e13335.
[18] Cantero I, Elorz M, Abete I, et al. Ultrasound/Elastography techniques, lipidomic and blood markers compared to magnetic resonance imaging in non-alcoholic fatty liver disease adults[J]. Int J Med Sci, 2019, 16(1): 75-83.
[19] Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials[J]. BMJ Open, 2019, 9(3): e017995.
[20] 陈镇清, 赖清谊, 吕振梁. 瞬时弹性成像技术评价非酒精性脂肪性肝病经保肝抗纤治疗后肝脂肪变性与肝纤维化疗效[J]. 数理医药学杂志, 2020, 33(1): 44-45.
[21] Rajcic D, Brandt A, Cheng JJ, et al. Exchanging dietary fat source with extra virgin olive oil does not prevent progression of diet-induced non-alcoholic fatty liver disease and insulin resistance[J]. PLoS One, 2020, 15(9): e0237946.
[22] Cicero AFG, Sahebkar A, Fogacci F, et al. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial[J]. Eur J Nutr, 2020, 59(2): 477-483.
[23] 史文龙.多烯磷脂酰胆碱联合二甲双胍对非酒精性脂肪肝患者血清IL-17及TGF-β水平的影响观察[J]. 现代诊断与治疗, 2018, 29(21): 3427-3428.
[24] Zheng F, Cai Y. Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γand genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet[J]. Lipids Health Dis, 2019, 18(1): 6.
[25] 曾燕. 沙格列汀对2型糖尿病合并非酒精性脂肪性肝病患者肝脏炎性反应、肝纤维化和胰岛素抵抗的影响[J].吉林医学, 2020, 41(7): 1614-1616.
